Abstract
We present an unusual case of breast cancer with increased FDG uptake 4 months after
chemotherapy. A PET-CT scan displayed results that mimicked multiple lymph node metastases
in the right axilla, the mediastinum, and the bilateral pulmonary hilar regions. However,
the increased FDG uptake disappeared 17 months later without any additional medical
treatment, suggesting the occurrence of flare phenomenon.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?.J Clin Oncol. 1995; 13: 1470-1477
- Measuring [18F] FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.Eur J Nucl Med Mol Imaging. 2003; 30: 674-681
- PET/CT and breast cancer.Eur J Nucl Med Mol Imaging. 2004; 31: S135-S142
- FDG-PET in monitoring therapy of breast cancer.Eur J Nucl Med Mol Imaging. 2004; 31: S112-S117
- The role of PET in monitoring therapy.Cancer Imaging. 2005; 5: 51-57
- Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy.J Clin Oncol. 2000; 18: 1676-1688
- Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.J Nucl Med. 2003; 44: 1806-1814
- Positron emission tomography assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy.Eur J Nul Med. 1999; 26: 51-56
- Measurement of clinical and subclinical tumor response using 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group.Eur J Cancer. 1999; 35: 1773-1782
- Defining co-related parameters between ‘metabolic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and establishing guidelines for assessing response to treatment in cancer.Eur J Nucl Med Mol Imaging. 2007; 34: 441-443
Article info
Publication history
Published online: April 23, 2009
Accepted:
February 27,
2009
Received:
February 8,
2009
Identification
Copyright
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
